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The process of protein modiﬁcation by adding or detaching small ubiquitin-like modiﬁers (SUMO)
proteins, called SUMOylation, contributes to the regulation of numerous processes in eukaryotic cells.
SUMOylation also represents a key response and adaption mechanism to different forms of metabolic
stress. The central nervous system (CNS) and neurons in particular are highly susceptible to hypoxic-
ischemic stress due to the lack of signiﬁcant oxygen and energy reserves. SUMOylation is observed in
many molecular responses to metabolic stress in the brain, and is therefore supposed to represent an
endogenous neuroprotective mechanism. However, the detailed roles of SUMOylation during CNS
hypoxia-ischemia are not well understood so far. Moreover, SUMOylation is subjected to complex reg-
ulatory mechanisms and might exert protective, but also detrimental processes during hypoxic-ischemic
stress.
This review provides a comprehensive overview on SUMOylation processes under physiological and
pathological conditions in the CNS. A particular spotlight is set on clinically relevant hypoxic-ischemic
conditions such as stroke by focusing on peri- and postischemic SUMOylation in neurons and astro-
cytes. The review describes relevant SUMOylation targets in these cells to discuss conﬁrmed and sup-
posed downstream mechanisms potentially contributing to neuroprotection, but also to sometimes
detrimental processes. The review further provides unique insights into the time course of SUMO re-
sponses during cerebral ischemia in different cerebral cell populations. This includes neurons, astrocytes,
but also phagocytes that become activated (microglia) and/or migrate (macrophages/monocytes) to the
ischemic CNS. Based on this compact knowledge, the review ﬁnally suggests potential directions for
future basic and translational research.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
2. Physiological functions of SUMOylation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
3. Pathophysiological functions of SUMOylation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
4. SUMOylation under hypoxic-ischemic conditions in the central nervous system . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
5. Roles and functions of SUMOylation in neurons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
5.1. SUMOylation of transcription factors during hypoxia-ischemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
5.2. SUMO and NFkB signaling: regulation of neuroinflammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
5.3. SUMO and oxidative stress: a Janus-faced mechanism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69nal Medicine and Cell Tech-
otechnology, M€onkhofer Weg
e (J. Boltze).
Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
M. Peters et al. / Neurochemistry International 107 (2017) 66e77 675.4. SUMOylation and mitochondrial functionality . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
5.5. SUMOylation of ion channels, receptors and membrane proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
5.6. SUMOylation and posttranslational modifications in the ischemic stress response . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
6. SUMO signaling and astrocytic functions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
7. Post-ischemic SUMO expression in microglia and phagocytes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
8. SUMOylation and post-stroke recovery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
9. Conclusions and future research directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
Acknowledgements and funding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 751. Introduction
Posttranslational modiﬁcations are a fast and efﬁcient cellular
mechanism to react on pathophysiological stimuli. Next to well
described processes such as phosphorylation and ubiquitination,
dynamic protein modiﬁcation by adding or detaching of 11 kDa
small ubiquitin-like modiﬁers (SUMO) proteins represents a key
regulatory and response mechanism in eukaryotic cells (Dorval and
Fraser, 2007). SUMO proteins covalently bind to lysine residues on
target proteins via a multi-step enzymatic cascade. This process is
called SUMOylation and requires a SUMO-activating enzyme E1, a
SUMO-speciﬁc conjugating enzyme E2 (Ubc9), and a SUMO ligase
E3 (Geiss-Friedlander and Melchior, 2007). Four subtypes (SUMO-1
to SUMO-4) have been identiﬁed in human cells. SUMO-1 (15% of
expressed isoforms) exhibits a 47% homology to SUMO-2 and 3
(70% and 15% of expressed isoforms, respectively). SUMO-2 and -3
show a 95% homology, and are therefore often referred to as
SUMO2/3. SUMO-2 and -3 appear to act very similar if not redun-
dantly. SUMO -1, 2 and 3 are expressed ubiquitously and can be
detected in the vertebrate brain. SUMO-4, which is less well
investigated, is mainly expressed in kidney and liver, but not in the
brain (Bohren et al., 2004; Hay, 2005).
SUMOylation is a reversible process and de-conjugation is
mediated by SUMO-speciﬁc proteases (SENPs). The balance be-
tween Ubc9-mediated conjugation and SENP mediated de-
conjugation changes the functional properties of the target pro-
teins. For example, SUMOylation of target proteins can affect their
intracellular localization, activity and stability as well as interaction
with other proteins (Deyrieux et al., 2007; Geiss-Friedlander and
Melchior, 2007; Johnson, 2004; Loriol et al., 2012; Xu et al., 2008).
Both SUMO-1 and SUMO-2/3 use the same conjugation mecha-
nism. A large pool of non-conjugated SUMO-2/3 proteins is usually
available in the cell, and SUMO-2/3 proteins are conjugated to
different target proteins during and after cellular stress (Saitoh and
Hinchey, 2000). In contrast, SUMO-1 is rarely detected unbound
(Meulmeester and Melchior, 2008).
An increasing body of evidence underlines the key regulatory
roles exerted by SUMOylation in numerous metabolic processes in
the central nervous system (CNS) (Dorval and Fraser, 2007; Martin
et al., 2007b). However, its role during hypoxic-ischemic stress is
less well known and only partly understood, as are the spatial
temporal proﬁles of SUMOylation in hypoxic-ischemic stress. This
review summarizes the current state of knowledge on physiological
and pathophysiological functions of SUMOylation in the CNS, and
highlights its effects on the cellular counter-balance of hypoxic-
ischemic injury.
2. Physiological functions of SUMOylation
Several hundred SUMO substrates have been identiﬁed so far.
Many SUMO substrates were identiﬁed in the nucleus, but othersare detected in the cytoplasm, mitochondria and the cell mem-
brane (Tempe et al., 2008). The majority of SUMO targets are
transcription factors, co-activators, or -suppressors. SUMOylation
has also been described to play a role in chromatin modeling, DNA
repair, telomere maintenance, as well as intracellular transport and
signaling (Flotho and Melchior, 2013; Hay, 2005). SUMO further
participates in the regulation of the cell cycle and mitochondrial
activity (Andreou and Tavernarakis, 2009; Harder et al., 2004).
Eukaryotic cells require SUMO activity for maintaining physiolog-
ical functions and survival, but not all isoforms are equally required
for this. For example, SUMO-2 can compensate for a lack of SUMO-1
in mice (Evdokimov et al., 2008; Zhang et al., 2008) and even for a
lack of SUMO-3 if expressed in sufﬁcient quantities (Wang et al.,
2014b). In turn, SUMO-2/ animals do not survive embryonic
day E10.5 (Wang et al., 2014b).
Dynamic SUMOylation also plays a central role in neural cell
differentiation and synaptogenesis in the CNS (Shalizi et al., 2006).
For instance, SUMO exerts a direct inﬂuence on axonal mRNA
transport and protein synthesis, thereby inﬂuencing axonal
regeneration including growth cone orientation, and synaptic
plasticity (van Niekerk et al., 2007). Moreover, numerous iono- and
metabotropic membrane receptors, potassium channels and
glucose transporters (GLUT) can be SUMOylated, indicating a pro-
found regulatory inﬂuence of SUMOylation on ion ﬂow/distribu-
tion, resting potentials and neuronal excitability (Loriol et al., 2012;
Martin et al., 2007b; Scheschonka et al., 2007; Wilkinson et al.,
2010). Moreover, SUMOylation can regulate transmitter release
(Feligioni et al., 2009) and synaptic transmission. Table 1 summa-
rizes processes and proteins subjected to SUMO regulation in the
CNS.
3. Pathophysiological functions of SUMOylation
Due to the abundance of SUMO-regulated processes, functional
SUMOylation deﬁcits are associated with severe diseases and
congenital malformation (Alkuraya et al., 2006; Bettermann et al.,
2012). Since SUMO regulates growth, differentiation, ageing and
apoptosis on a cellular level, it is not surprising that deﬁcits in
SUMO functionality can contribute to tumorigenesis (Deyrieux
et al., 2007; Gill, 2005; Ihara et al., 2007). Indeed, tumor suppres-
sor gene p53 and oncogenic transcription factors c-Jun and c-Fos
present important SUMO substrates, but the exact role of their
SUMOylation is still discussed controversially (Bettermann et al.,
2012).
SUMOylated proteins have been identiﬁed within pathological
protein aggregates in the brain while disease-speciﬁc proteins in
neurodegenerative diseases are often SUMOylation targets
(Table 2). SUMO has been identiﬁed as a key regulator of numerous
disease-relevant protein speciﬁcations such as localization, func-
tion, degradation, misprocessing, solubility, and aggregation
(Dorval and Fraser, 2007). Metabolic stress clearly impacts
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inﬂuence. Even the presence of minor amounts of hydrogen
peroxide (H2O2; <1 mM) can induce the almost complete loss of
SUMO conjugates (Bossis and Melchior, 2006a; 2006b). Inhibition
of SUMOylation under oxidative stress conditions can facilitate
normalization of the cellular redox state by inducing expression of
several anti-oxidative proteins via c-Fos and c-Jun. The sensitivity
of SUMOylation for oxidation-borne inactivation is believed to be of
physiological relevance for redox signaling processes such as
endogenous H2O2 production in phagocytes (Bossis and Melchior,
2006a).
4. SUMOylation under hypoxic-ischemic conditions in the
central nervous system
Metabolic stress as induced by hypoxia or hypothermia in-
creases SUMOylation in the brain (Lee et al., 2009a; Yang et al.,
2008a,b, 2009; Cimarosti et al., 2008) under physiological and
pathophysiological conditions. For instance, a massive increase of
SUMO-1- and SUMO-2/3-based SUMOylation is observed in hi-
bernating ground squirrels (Lee et al., 2007). The reduced cerebral
blood ﬂow and consecutively reduced oxygen and glucose levels in
the hibernating brain can be considered as a natural and mild
model of cerebral hypoperfusion, and structural brain damage does
not occur in the presence of SUMOylation.
An increased nuclear accumulation of SUMO-2/3 in cortical
neurons was detected after hypothermia in the rat brain (Wang
et al., 2012). Moreover, SUMO-1 overexpression in cultured ro-
dent primary cortical neurons increases cell survival under oxygen
glucose deprivation (OGD) while RNAi-mediated inhibition of
SUMO-1 and SUMO-2/3 expression increases cell loss (Lee et al.,
2009a; Datwyler et al., 2011). In turn, an increase in global
SUMO-conjugation was reported as a main mechanism of
hypothermia-mediated SHSY5Y cell and rodent cortical neuron
protection during OGD in vitro. Subsequent in vivo studies
conﬁrmed these results. Hypothermic treatment of mice before and
after permanent middle cerebral artery occlusion (pMCAO)
elevated cerebral SUMO-conjugation levels, what was accompa-
nied by a decrease of ischemic lesion size (Lee et al., 2014b).
Transgenic Ubc9 mice overexpress the E2 SUMO conjugating
enzyme and thereby display elevated basal levels of global
SUMOylation even in the steady state. These mice exhibit signiﬁ-
cantly smaller lesion volumes without hypothermia which, how-
ever, could not be further decreased by hypothermic treatment (Lee
et al., 2014b). These data strongly suggest that SUMOylation is
indeed a major mechanism of hypothermia-induced neuro-
protection. The idea that global SUMO conjugation is an important
component of ischemic tolerance was further supported by a recent
study using neuron-speciﬁc SUMO 1e3 knock down (SUMO-KD)
mice. SUMO-KD mice exhibited signiﬁcantly worse functional
outcomes after transient forebrain ischemia. Moreover, post-
ischemic gene expression was widely affected in SUMO-KD mice
showing an overall reduced expression (Zhang et al., 2017).
The SUMO response to ischemic stimuli is rapid. Only 10 min of
transient forebrain ischemia in mice lead to a measurable increase
of SUMO-2/3 conjugation in cortical and hippocampal neurons
whereas unbound SUMO-2/3 is decreased. A strong activation of
SUMO-1 and SUMO-2/3 in the infarct border zone was observed
already 6 and 24 h following reperfusion in a rat model of transient
focal cerebral ischemia. Next to activation in the directly affected
striatum, SUMO-2/3 was also increased in the hippocampus, not
directly affected by ischemia in this model (Cimarosti et al., 2008).
Increase of SUMO-2/3-based, but not SUMO-1-based SUMOylation
has also been described after transient ischemia in the spinal cord
(Wang et al., 2013). Taken together, these data suggest a protectiverole of SUMOylation under different hypoxic-ischemic conditions
in neurons and in different brain areas (Datwyler et al., 2011). Fig. 1
illustrates typical spatial and temporal patterns of SUMO expres-
sion after cerebral ischemia induced by pMCAO. Images were ob-
tained in own, unpublished experiments.
5. Roles and functions of SUMOylation in neurons
Although an increasing body of evidence suggests an important
role of SUMOylation as an endogenous neuroprotective mecha-
nism, potential underlying mechanisms require more detailed
discussion. A plethora of transcription factors, transporter proteins,
ion channels and receptors respond to or even counteract hypoxic-
ischemic stress. Many of those are modulated by SUMOylation.
There is a massive SUMO activation after hypoxic-ischemic injury
(Fig. 1) and numerous regulators and pathways that play a signiﬁ-
cant role in the response to brain ischemia are SUMOylation targets.
However, this does not provide direct evidence that SUMOylation is
indeed a part of the response to hypoxic-ischemic injury in the
brain although SUMOylation plays a role in the ischemic stress
response via these factors in other organs. It is nevertheless
appealing to consider these potential mechanism concepts in order
to inform future research addressing novel targets for neuro-
protective interventions.
5.1. SUMOylation of transcription factors during hypoxia-ischemia
SUMOylation activates or represses many transcription factors
(Lyst and Stancheva, 2007). One prominent example of a hypoxic
signaling cascade mediator is the hypoxia-inducible factor (HIF)-1,
which serves as a transcription factor and participates in the
adaption to low oxygen concentration. HIF-1 contains an oxygen-
regulated a-subunit as well as a constitutively expressed b-sub-
unit. It helps to regulate glucose metabolism and genes enrolled in
angiogenesis (Nú~nez-O'Mara and Berra, 2013). HIF-1a, HIF-1b and
HIF-2a are substrates of SUMO-1 and SUMO-2/3, but activity and
stability of the resulting constructs are discussed controversially
(Silveirinha et al., 2013). Hypoxia induces HIF-1a SUMOylation,
which promotes HIF-1a degradation. The SUMO protease SENP-1
deconjugates SUMOylated HIF-1a and allows HIF-1a to escape
degradation and thereby promotes hypoxia-induced transcription
of HIF-1a-dependent genes in ﬁbroblasts (Cheng et al., 2007). A
deﬁcit of the SUMO protease SENP-1 impairs the protective HIF-1
signaling cascade and aggravates post-ischemic reperfusion dam-
age inmyocardial cells (Gu et al., 2014). HIF-1 is activated after focal
cerebral ischemia in the adult rat brain (Sharp et al., 2001). This
suggests HIF-1 as a potent mediator of neuroprotection, with its
function crucially depending on SUMOylation. However, any
functional studies to address this hypothesis are yet lacking.
The transcription of heat shock proteins is controlled by SUMO
via heat shock factor protein 1 (HSF-1) regulation. This is of po-
tential relevance for cerebral ischemia since HIF-1 can protect
ischemic myocardial tissue, and is activated by oxygen and glucose
deprivation (OGD) in astrocytes (Bergeron et al., 1996). Heat shock
stimulates SUMO-2/3, but not SUMO-1 conjugation, and SUMO-1
cannot compensate the function of SUMO-2/3 under these condi-
tions. This underlines the assumption that SUMO-2/3 is more
prevalent and important than SUMO-1 during hypoxic-ischemic
stress (Golebiowski et al., 2009; Saitoh and Hinchey, 2000). On
the other hand, the nuclear factor erythroid 2-related factor (Nrf)-2,
a transcription factorwhich is essential for the response to hypoxic-
ischemic stress (Patel and Chu, 2011) by controlling the expression
of glutathione and super-oxide dismutase, is a substrate of both
SUMO-1 and SUMO-2/3 (Malloy et al., 2013). Moreover, a recent
report has shown that NQO1, a key enzyme downstream of Nrf-2,
Table 1
SUMO-regulated CNS proteins.
SUMO-regulated target protein Function References
axin: activation of c-Jun NH(2)-terminal kinase (JNK)
signaling
regulation of phosphorylation Rui et al., 2002
cannabinoid receptor 1 synaptic transmission Gowran et al., 2009
CASK (peripheral plasma membrane protein) synaptic transmembrane protein anchoring, ion channel trafﬁcking, dendritic
spine morphology
Chao et al., 2008
caspase 7 apoptosis Hayashi et al., 2006
caspase 8 apoptosis Besnault-Mascard et al., 2005
coilin (survival of motor neuron (SMN) protein in Cajal
bodies)
pre-mRNA processing Navascues et al., 2008
dynamin-related protein 1 (DRP-1) mitochondrial ﬁssion during mitosis Figueroa-Romero et al., 2009;
Zunino et al., 2009
focal adhesion kinase (linking cytoskeleton to
extracellular matrix)
regulation of phosphorylation Mitra et al., 2005
glial excitatory amino acid transporter 2 (EAAT-2) modulation of glutamate transport Foran et al., 2014
glucose transporter GLUT-1 and GLUT-4 glucose transport Giorgino et al., 2000; Liu et al.,
2007
glycogen synthase kinase 3b (GSK 3b) regulation of phosphorylation Eun Jeoung et al., 2008
kainate receptor subunit GluK2 synaptic transmission Martin et al., 2007a
K2P1 potassium channel modulation Plant et al., 2012; Rajan et al.,
2005
Kv1.5 potassium channel modulation Benson et al., 2007
Kv2.1 potassium channel modulation Dai et al., 2009; Plant et al.,
2011
metabotropic glutamate receptor 8 (mGluR8) synaptic transmission Dütting et al., 2011
mRNA binding protein La axonal mRNA transport van Niekerk et al., 2007
myocyte enhancer factor 2 A (MEF-2A) postsynaptic differentiation Shalizi et al., 2007; Shalizi et al.,
2006
protein tyrosine phosphatase 1B (PTB1B) regulation of phosphorylation, hypothalamic regulation of food intake and body
weight
Dadke et al., 2007
Table 2
SUMOylation in neurodegenerative diseases.
Neurodegenerative disease SUMO substrate Reference
Alzheimer's disease tau Dorval and Fraser, 2006
amyloid precursor protein Zhang and Sarge, 2008; Li et al., 2003
Amyotrophic lateral sclerosis super oxide dismutase 1 Fei et al., 2006
glial excitatory amino acid transporter 2 (EAAT-2) Foran et al., 2011
Huntington's disease huntingtin Steffan et al., 2004
Parkinson's disease tau, a-synuclein Dorval and Fraser, 2006
DJ-1 (PARK7) Shinbo et al., 2006; Zhong et al., 2006
Spinocerebellar ataxia ataxin-1 Riley et al., 2005; Ryu et al., 2010
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Blocking of Nrf-2 by decoy double-stranded oligonucleotides (ODN)
counteracts the effect of neuroprotective drugs afterMCAO (Li et al.,
2017). SUMOylation may therefore also be enrolled in the regula-
tion of the ischemic stress response via Nrf-2.
5.2. SUMO and NFkB signaling: regulation of neuroinﬂammation
Nuclear factor kappa-light-chain-enhancer of activated B cells
(NFkB) is an important regulator of the immune response. NFkB is
expressed in neurons and becomes activated during ischemia.
Under normoxic conditions, NFkB is silenced by the inhibitory
factor IkB. IkB itself is phosphorylated and conjugated by ubiquitin,
leading to its degradation and consecutive NFkB activation. A
SUMO-1-conjugation stabilizes IkB and inhibits excessive NFkB
activation, but SUMO-2/3 conjugation fosters dissociation of NFkB
from IkB, leading to its activation. This is associated by a stronger
inﬂammatory response and neuronal apoptosis in the hypoxic-
ischemic brain (Schneider et al., 1999). However, more recent in-
vestigations surprisingly also revealed a neuroprotective activity of
NFkB reducing lesion volume after stroke (Li et al., 2008). These
contrary results require clariﬁcation and may point at a so far un-
known, additional regulator of NFkB under hypoxic-ischemicconditions, what could partially explain the antagonistic functions
of SUMO subtypes.
5.3. SUMO and oxidative stress: a Janus-faced mechanism
SUMO proteases can be reversibly and irreversibly modiﬁed
under conditions of oxidative stress. The balance between
SUMOylation and de-SUMOylation can be shifted towards the latter
to stabilize oxidative homeostasis (Xu et al., 2008). This is of rele-
vance since de-SUMOylation of transcription factors c-Fos and c-
Jun enhances their activity and thereby the expression of anti-
oxidative proteins under oxidative stress (Bossis et al., 2005; Müller
et al., 2000). Further, the c-Jun N-terminal kinase (JNK) and
downstream signaling pathways play a key role in the induction of
apoptosis under oxidative stress. Since JNK signaling is strongly
activated after cerebral ischemia, its blockage protects neurons in
infarct border zones and the hippocampus from reperfusion dam-
age (Zhang and Chen, 2008). Ataxin-1 is a potent JNK pathway
activator. Successful inhibition of the JNK signaling pathway re-
duces the oxidant-mediated SUMOylation and aggregation of
ataxin-1, providing a considerable negative feedback loop being of
importance for instance in spinocerebellar ataxia (Ryu et al., 2010).
Moreover, JNK itself is a SUMO-1 substrate. Hence, increased
M. Peters et al. / Neurochemistry International 107 (2017) 66e7770SUMOylation by SUMO-1 contributes to pro-apoptotic mechanisms
under oxidative stress. On the other hand, SUMOylation of target
proteins can also exert protective mechanisms under oxidative
stress. For instance, strong expression of SUMO-1 dampens pro-
duction of reactive oxygen species (ROS) by reducing p38, and
SUMO-1-based SUMOylation of NADPH-oxidase 2 indirectly re-
duces intracellular production of ROS (Kim et al., 2011; Silveirinha
et al., 2013). This dynamic regulation is considered to be key mo-
lecular switch in the regulation of the cellular response to oxidative
stress. The ﬁne balance between SUMOylation and de-
SUMOylation are complex and not well understood yet (Feligioni
and Nistico, 2013), while the relevance of the discussed pathways
remain to be conﬁrmed for cerebral ischemia-hypoxia.
5.4. SUMOylation and mitochondrial functionality
Apoptosis and autophagy take place in the ischemic penumbra
due to oxygen and glucose deprivation (Rami and K€ogel, 2008;Wen
et al., 2008). Many proteins enrolled in this processes as well as a
number of DNA repair proteins are SUMO substrates (Cajee et al.,
2012). Mitophagy (mitochondrial autophagy) fosters ischemic
damage because mitochondrial degradation leads to an increased
release of ROS and subsequent cellular damage (Pamenter et al.,
2012). Mitochondria further play a pivotal role in the cellular
response to ischemic stressors as they can increase their number by
division and proliferation, increasing the cell's capacity to produce
ATP. Mitochondria are also important for synapse maintenance and
activity (Li et al., 2004). A central regulator protein of mitochondrial
division is dynamin-related protein (DRP)-1, which mediates
membrane cutting during mitochondrial ﬁssion (Smirnova et al.,
2001). DRP-1 is a SUMO substrate. SENP-5-regulated de-
SUMOylation leads to oligomerization of DRP-1 helping to control
the ﬁssion process, what is particularly relevant for cell mitosis
under physiological conditions (Zunino et al., 2009). However,
SENP-5 inactivity leads to increased production of ROS, underpin-
ning the important role of the SENP-5-SUMO-axis for theFig. 1. Temporal and spatial SUMO expression proﬁles in neurons. (A) and (B) Coronal section
3 (B) 1, 4 and 7 days after permanent middle cerebral artery occlusion (pMCAO) in the rat. T
high SUMO expression. (C) and (D) Expression of SUMO-1 (C) and SUMO-2/3 (D) in Fluoro-N
the ischemic lesion. Nuclei in (C) and (D) were counterstained with DAPI (blue), and [II] to [IV
separately beneath in a higher magniﬁcation. Scale bars: 1 mm (A, B), 20 mm (C, D). All ima
from rats subjected to permanent middle cerebral artery occlusion as described elsewher
methodological details is available with this publication.mitochondria-based compensation of oxidative stress. Whether or
not these processes are also of relevance for the cellular response to
hypoxia-ischemia in the CNS remains to be investigated. However,
another and to some extent contrary process has been described as
a neuroprotective mechanism under metabolic stress. The SUMO-
2/3-speciﬁc protease SENP-3 is degraded during OGD, what ex-
tends SUMOylation of DRP-1. This in turn suppresses the DRP-1-
mediated release of cytochrome C and caspase-mediated
apoptotic cell death. The dynamic regulation of DRP-1 via the
SENP-3-SUMO-2/3-axis therefore represents an adaptive pathway
to extreme cellular stress in neurons (Guo et al., 2013).
5.5. SUMOylation of ion channels, receptors and membrane
proteins
Next to its nuclear activities, SUMO contributes to the extra-
nuclear modulation of transporter proteins, ion channels and re-
ceptors. It therefore plays a role for the homeostasis of neuronal
metabolism, but also for the regulation of excitability and trans-
mitter release in the steady state. For instance, the de-SUMOylation
of voltage-gated Kv1.5 potassium channels induces a selective
hyperpolarizing shift in voltage-dependency, thereby leading to a
functional inactivation of these channels (Benson et al., 2007). This
inactivation is an energy-saving process under hypoxic-ischemic
conditions and dramatically increases ischemic tolerance in neu-
rons. Hence, the SUMO-mediated inactivation of voltage-gated
potassium channels is considered as a relevant neuroprotective
mechanism (Stapels et al., 2010). Voltage-dependent Kv2.1 potas-
sium channels initiate apoptotic signaling cascades in cortical
neurons. (Pal et al., 2003). Conjugation of Kv2.1 channels by SUMO-
1 and SUMO-2/3 modulates channel opening and voltage-gating
(Plant et al., 2011). The resulting reduction of excitability is an
efﬁcient neuroprotective mechanism in neurons experiencing
hypoxic-ischemic stress (Silveirinha et al., 2013).
The role of SUMOylation on sodium membrane trafﬁc under
hypoxic-ischemic conditions is a double-edged sword. The sodium/s of the ipsilateral hemisphere of the rat brain. Expression of SUMO-1 (A) and SUMO-2/
he infarct is clearly seen in the parietal cortex. Arrows point at locations with relatively
issl-positive neurons 4 days after pMCAO. SUMO expression is highest in areas close to
] correspond to locations as given in Fig. 3A. Regions marked by a square are displayed
ges obtained from own, unpublished experiments. The brain specimens were derived
e (Riegelsberger et al., 2011; Wagner et al., 2011). Supplementary material describing
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cerebral ischemia. Knockdown of NCX3 exacerbates ischemic
damage induced by pMCAO and transient (t)MCAO (Pignataro et al.,
2004; Molinaro et al., 2008). On the one hand, SUMO-1 directly
interacts with NCX3. SUMO-1 conjugation pattern signiﬁcantly
increase in response to ischemia in the cortex, and silencing of
SUMO-1 signiﬁcantly increases the ischemic damage induced by
tMCAO in the rodent brain (Cuomo et al., 2016). On the other hand,
it was recently shown that SUMOylation of NaV1.2, an a-subunit of
voltage-gated sodium (Nav) channel that is widely distributed in
the brain, underlies the immediate increase in voltage-gated so-
dium inward current (INa) in cultured cortical neurons under
hypoxic-ischemic conditions (Plant et al., 2016). Sodium inﬂux is
well known to be a key trigger of neuronal damage under hypoxic-
ischemic conditions, what illustrates that SUMOylation under these
circumstances can exert both, protective and detrimental effects.
Hence SUMOylation may be a complex therapeutic target to
address in an attempt to optimize SUMOylation-mediated
neuroprotection.
Kainate receptors contribute to ischemic cell damage. Neuro-
protection can be exerted by the knockdown of the GluK2 kainate
receptor subunit under OGD (Pei et al., 2006). SUMOylation reduces
GluK2-induced excitation by subunit internalization at the post-
synaptic membrane and thus contributes to neuroprotection.
Indeed, global cerebral ischemia causes a massive increase in
SUMOylation of GluK2, followed by endocytosis of kainate re-
ceptors (Zhu et al., 2012). SUMOylation does not only reduce the
AMPA- and kainate receptor subunits GluR2/3 and GluR6/7 in the
ischemically affected cortex and striatum, but also reduces GluR2/3
in the hippocampus after stroke (Cimarosti et al., 2008). SUMOy-
lation has therefore a profound impairing effect on glutamate-
mediated signaling, helping to counterbalance ischemic excito-
toxicity in the brain. However, the internalization of AMPA-and
kainate receptor subunits also activates JNK signaling, which has
been described as an important contributor to ischemic neurotox-
icity and apoptosis (Zhu et al., 2012).
SUMOylation further exerts neuroprotective effects by modu-
lation of other receptor types. Metabotropic glutamate receptors
modulate synaptic transmission and are believed to mediate neu-
roprotective effects (Caraci et al., 2012). The group-III glutamate
receptor mGluR8b is a SUMO-1 substrate and its SUMOylation is
likely an element of the self-protective response to hypoxic-
ischemic damage in neurons (Dütting et al., 2011). SUMOylation
of the cannabinoid receptor CB-1 is involved in the regulation of
p53, which in turn is important for apoptosis under metabolic
stress. Of note, CB-1 is a constitutive SUMO substrate and its de-
SUMOylation is mediated by agonistic activation (Gowran et al.,
2009). This leads to p53 activation, steeply increasing neuronal
cell death during ischemia (Yonekura et al., 2006).
Interestingly, opposing effects were observed for the SUMOy-
lation of glycogen synthase kinase 3b (GSK-3b). SUMO modulates
subcellular localization, stability and kinase activity of GSK-3b,
making affected cells more susceptible to apoptotic stimuli. In turn,
inactivation of GSK-3b enhances neuroprotection after stroke,
decreasing ischemic infarct size. GSK-3b inactivation also reduces
the inﬂammatory response to cerebral ischemia (Collino et al.,
2008; Zhou et al., 2011). On the other hand, GSK-3b phosphory-
lates the estrogen receptor b (ER-b), maximizing its SUMOylation
(Picard et al., 2012). This enhances ER-b stability, what ﬁnally
mitigates ischemic damage and blood-brain barrier disintegration.
This is another good example for the rather complex mechanisms
that might potentially be exerted by SUMOylation under hypoxic-
ischemic stress in the CNS exerting both beneﬁcial and detri-
mental effects.5.6. SUMOylation and posttranslational modiﬁcations in the
ischemic stress response
The complexity of SUMOylation effects is further exempliﬁed by
its interplay with posttranslational modiﬁcations. This is of
particular relevance for the cellular response to hypoxic-ischemic
stressors. Structural and functional similarities of SUMO and
ubiquitin can lead to competitive and interdependent conjugations
at the same sites of joint substrates. This may even result in
sequential modiﬁcations of target proteins in the same signaling
pathway and thereby exerting antagonistic or synergistic effects
(Praefcke et al., 2012). Activation proﬁles of SUMO and ubiquitin
following ischemia are similar. In contrast to SUMO-1, SUMO-2/3
and ubiquitin accumulate in insoluble protein aggregates following
ischemia (Hochrainer et al., 2015). Both, ubiquitin and SUMO-3
bind to lysine residues of numerous joint substrates. Experiments
with SUMO-transgenic mice indicate that the interplay between
SUMO and ubiquitin is activated following cerebral ischemia, which
has neuroprotective effects and reduces reperfusion injury. There is
also a SUMOylation-dependent ubiquitin conjugation of target
proteins, which can be dramatically increased following cerebral
ischemia, and can be blocked by silencing SUMO-2/3 expression
(Yang et al., 2014). SUMOylation itself contributes to the repair of
DNA double helices and SUMOylation of DNA repair proteins is
directly triggered by DNA damage. Poly-SUMOylated proteins are
substrates of the SUMO-targeted ubiquitin ligases, which interlink
SUMOylation and ubiquitin conjugation, and play a pivotal role in
genome stability (Prudden et al., 2007). The NFkB inhibitory factor
ikBa is an important substrate of competitive conjugation by SUMO
proteinases, ubiquitin and phosphorylation. The phosphorylation-
dependent ubiquitin conjugation mediates ikBa degradation. This
is counter-acted by SUMOylation, which enhances the molecule's
stability. This in turn inhibits activation of NFkB, what can increase
neuroinﬂammation and causes detrimental effects during neuronal
ischemia (Desterro et al., 1998; Emmanouil et al., 2011; Schneider
et al., 1999).
In summary, SUMOylation is a pleiotropic regulator exerting
complex effects in response to hypoxic-ischemic injury in the brain
which are further complicated by a puzzling interplay with other
factors and pathways. SUMOylation can have both beneﬁcial and
deleterious consequences, but fosters neuronal survival in the
hypoxic ischemic brain. A detailed investigation of the underlying
mechanisms and pathways is required to identify new molecular
targets for future drug discovery in order to fully exploit the neu-
roprotective potential of SUMOylation. Fig. 2A summarizes relevant
activities of SUMOylation in the post-ischemic neuron.
6. SUMO signaling and astrocytic functions
SUMOylation under hypoxic-ischemic conditions has been
described for astrocytes in the brain, but the impact of SUMOyla-
tion on glial function is less well known. Our studies have shown
that reactive astrocytes exhibit strong SUMO-1 and SUMO-2/3
immunoreactivity in the infarct border zone following permanent
middle cerebral artery occlusion pMCAO in the rat (Fig. 3). An in-
crease of nuclear SUMO-1 was observed 2 days after pMCAO,
whereas an increase in SUMO-2/3 was seen after 3 days. A delayed
upregulation of SUMO-2/3 as compared to SUMO-1 was already
described for hippocampal neurons (Cimarosti et al., 2012). SUMO-
1/2/3 immunoreactivity decreased at day 7 following pMCAO. The
distinct activation patterns of SUMO in astrocytes following stroke
points at important functions of SUMOylation also for the astroglial
response to hypoxic-ischemic stress.
One study conﬁrmed the presence of SUMO-1 in astrocytes
(Akar and Feinstein, 2009). Overexpression of SUMO-1 inhibits b-
Fig. 2. Effects of SUMOylation under hypoxia-ischemia in neurons and astrocytes. (A) summarizes known potential SUMOylation targets in neurons being of relevance for post-
ischemic neuroprotection. (B) provides an overview on relevant SUMOylation targets in astrocytes. Protective effects of SUMOylation on neurons and/or other neural cell pop-
ulations are given in green, while red font indicates SUMOylation effects aggravating hypoxic-ischemic cell damage or targets which exert protective functions after deSUMOylation.
Orange font indicates targets that can exert both, protective and detrimental effects after SUMOylation. Mechanisms still discussed controversially in literature regarding impact and
overall relevance are given in grey font. Abbreviations: cFOS, cJUN: proto-oncogenes and elements of activator protein 1; DRP-1: dynamin-related protein 1; EAAT-2: excitatory
amino acid transporter 2, a glutamate transporter; ER-b: estrogen receptor b; GLUT-1: glucose transporter 1; GR: glucocorticoid receptor; GSK-3b: glycogen synthase kinase 3b; HIF:
hypoxia-inducible factor; HSF-1: heat shock factor protein 1; JNK: c-Jun N-terminal kinase; MEF-2A: myocyte-speciﬁc enhancer factor 2A; NFkB: nuclear factor kappa-light-chain-
enhancer of activated B cells; Nrf-2: nuclear factor erythroid 2erelated factor 2; SIRT-1: Sirtuin 1.
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reduces expression of the astrocytic, pro-inﬂammatory NO-syn-
thase (Akar and Feinstein, 2009). The early expression of SUMO-1 in
astrocytes might therefore represent an anti-inﬂammatory
response. The NAD-dependent deacetylase Sirtuin (SIRT)-1 atten-
uates apoptosis, oxidative stress and inﬂammation in both astro-
cytes and neurons, for example by downregulating of p53 and
NFkB. This signiﬁcantly contributes to protective effects under
hypoxic-ischemic stress (Cheng et al., 2014). SIRT-1 is a SUMO-1
substrate and its SUMOylation is responsible for cardioprotective
effects and is upregulated during myocardial ischemic pre-
conditioning (Stastna and Van Eyk, 2015). Hence, the SUMOylated
SIRT-1 is also thought to be responsible for protective mechanisms
in the ischemic CNS.
The excitatory amino acid transporter 2 (EAAT-2), a glutamate
transporter, is predominantly expressed by astrocytes. EAAT-2 is
responsible for more than 90% of the glutamate uptake from the
synaptic cleft (Yamada et al., 2006). Hence, astrocytic EAAT-2 is an
important element of neuroprotection during ischemia. EEAT2 as a
whole molecule, but also its CTE fragment (resulting from cleavage
by caspase-3) are SUMO substrates. Of note, SUMOylation coun-
teracts neuroprotective effects of EAAT-2. The SUMOylated frag-
ment accumulates in astrocytic nuclei, which leads to a loss of
astrocytes and subsequently of motoneurons, for example duringthe course of amyotrophic lateral sclerosis (Foran et al., 2011). The
functional EAAT-2 protein is mainly located on the lipid rafts of
astrocytic protrusions (Melone et al., 2011). SUMOylated EAAT-2 is
translocated from the plasma membrane to the cytoplasm. This
decreases astrocytic glutamate uptake capacities what ultimately
aggravates neuronal excitotoxicity. The astrocytic estrogen receptor
a (ERa) is supposed to enhance glutamate uptake during ischemia.
Since SUMOylated ERa has a higher stability, SUMOylation may
increase astrocytic glutamate uptake activities (Picard et al., 2012).
Expression of ERa is regulated by GSK-3b, which exerts proin-
ﬂammatory effects as reviewed above. Increasing ERa stability by
SUMOylation rather than ERa expression may therefore be an
important astrocytic mechanism contributing to neuroprotection.
Ischemic stress causes activation of the glucocorticoid receptor
(GR), being associated with cellular damage during hypoxia-
ischemia (Balkaya et al., 2011). The receptor is also expressed on
astrocytes. JNK-mediated phosphorylation activates SUMOylation
of the GR what in turn reduces its activity, exerting protective ef-
fects (Davies et al., 2008; Yang et al., 2014). Glycogen is an impor-
tant alternative energy source in astrocytes. Astrocytes can process
glycogen to glucose and transport it to neurons (Brown and
Ransom, 2007). This is mediated by glucose transporters, particu-
larly GLUT-1. Insertion and stability of GLUT-1 in the plasma
membrane is regulated by the SUMO-E2 ligase UBc9, and SUMO-
Fig. 3. Temporal and spatial SUMO expression proﬁles in astrocytes. (A) Schematic drawing of rodent brain with ischemic lesion and regions of interest, [I]: inner lesion border zone,
[II]: outer lesion border zone, [III]: ipsilateral and [IV]: contralateral, unaffected brain tissue. (B) and (C) Expression of SUMO-1 (B) and SUMO-2/3 (B) in astrocytes of the outer lesion
border [II], in unaffected ipsilateral [III], and unaffected contralateral brain tissue [IV], all 4 days after permanent middle cerebral artery occlusion (pMCAO). SUMO is predominantly
expressed in areas close to the ischemic lesion in the rat brain. (D) and (E) Temporal expression proﬁle of SUMO-1 and SUMO-2/3 in the outer lesion border zone. Astrocytic SUMO
expression seems to peak around day 4. In contrast to SUMO-1, SUMO-2/3 expression is still strong at day 7 following pMCAO. Please note double-positive (SUMO-2/3þ and GFAPþ)
astrocytes in (C) and (E). Nuclei in (B) to (E) were counterstained with DAPI (blue). Scale bars: 20 mm. All images obtained from own, unpublished experiments. The brain specimens
were derived from rats subjectedto permanent middle cerebral artery occlusion as described elsewhere (Riegelsberger et al., 2011; Wagner et al., 2011).
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siently maintain energy neuronal supply via astrocytic “feeding”
during ischemia (Silveirinha et al., 2013). SUMO also supports
astrocytic dampening of inﬂammatory reactions. SUMOylation of
the Liver X receptor on astrocytes inhibits STAT-1 induced expres-
sion of IFN-g, TNF-a, and IL-6 what strongly mitigates neuro-
inﬂammation (Lee et al., 2009b). An overview of astrocytic function
being subject to SUMO regulation is given in Fig. 2B.7. Post-ischemic SUMO expression in microglia and
phagocytes
Ionized calcium binding adaptor molecule 1 (IBA-1) is a marker
of phagocytes, particularly for microglia and macrophages.
Increased SUMO expression is also observed in IBA-1-positive
phagocytes in the infarct border zone, which has been revealed
by studies from our lab. These cells are typically microglia orinvaded monocytes/macrophages, and also show the characteristic
delay in SUMO-2/3 activation (Fig. 4).
So far, however, only scattered knowledge is available regarding
the role of SUMOylation in phagocytes after hypoxic-ischemic
injury. Kv1.5 potassium channels, which were already discussed
with the neuronal SUMO expression, also control microglial pro-
liferation and the production of nitric oxide (Pannasch et al., 2006).
It may be speculated that the SUMO-mediated inactivation of
voltage-gated potassium channels as seen in neurons (Benson et al.,
2007) also plays a role for microglial function, but further research
is required to unravel its impact in more detail. In turn, endogenous
production of H2O2 in phagocytes during the inﬂammatory reaction
(oxidative burst) induces reversible inhibition of cytoplasmatic
SUMOylation and may even induce de-SUMOylation in certain
proteins or globally, depending on the H2O2 donor and amount
(Bossis and Melchior, 2006a). This indicates that SUMO functions
are strongly suppressed in these cells, butmore detailed knowledge
Fig. 4. Temporal SUMO expression proﬁle in IBA-1-positive phagocytes. (A) SUMO-positive cells appearing immunonegative for IBA-1 are found 1 day after experimental ischemic
stroke in the outer infarct border [II] in the rat. Next, SUMO-1 increases in parallel with the number of IBA-1-positive immune cells until day 7. (B) SUMO-2/3 expression is markedly
delayed and peaks around day 3. SUMO 2/3 expression does not further increase at day 7, even though the number of IBA-1 cells is increasing. Region [II] corresponds to location
given in Fig. 3A. Nuclei were counterstained with DAPI (blue). Regions marked by a square are displayed separately beneath in a higher magniﬁcation. Scale bars: 20 mm. All images
obtained from own, unpublished experiments. The brain specimens were derived from rats subjected to permanent middle cerebral artery occlusion as described elsewhere
(Riegelsberger et al., 2011; Wagner et al., 2011). Supplementary material describing methodological details is available with this publication.
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8. SUMOylation and post-stroke recovery
Neurofunctional deﬁcits are a predominant consequence of
hypoxic-ischemic brain injury. Brain plasticity allows the reorga-
nization of the lesioned brain and can help to partially regain
initially lost function. It is well known that SUMOylation is involved
in synaptic function and plasticity on numerous levels (Schorova
and Martin, 2016; Luo et al., 2013). Thereby, SUMOylation can
signiﬁcantly inﬂuence the establishment and maintenance of
complex neuronal networks. This is exempliﬁed in learning pro-
cesses, in which SUMOylation is required for long-term potentia-
tion (Lee et al., 2014a). In turn, SUMO-KD mice should have severe
impairments in memory formation (Wang et al., 2014a).
There is some indication that the inﬂuence of SUMOylation on
neural circuit build-up and maintenance is not restricted to
cognitive functions. Synapse formation is regulated by the interplay
between SUMOylation and acetylation, which is believed to be of
importance for the functional regeneration of post-ischemic
neuronal networks. The myocyte-speciﬁc enhancer factor 2 A
(MEF-2A) is a transcription factor being strongly expressed in the
brain. It exerts effects on neuronal differentiation and viability
(Heidenreich and Linseman, 2004). SUMOylation and phosphory-
lation of MEF-2A also affects differentiation of the postsynapse and
fosters synaptogenesis by suppressing MEF-2A activity. In turn,
calcium inﬂux induces dephosphorylation of MEF-2A by calci-
neurin, leading to de-SUMOylation and acetylation of a lysine res-
idue ﬁnally inhibiting synaptic differentiation (Shalizi et al., 2006),
what may hinder post-ischemic plasticity.
SUMOylation may hence be enrolled in plasticity-basedrecovery of sensor andmotor functions following hypoxic-ischemic
injury. It may therefore be speculated that the overall worse
functional outcome in SUMO-KD mice after cerebral ischemia as
discussed above (Zhang et al., 2017) may not only be due to lacking
endogenous neuroprotection, but to some extent also to impaired
post-ischemic brain plasticity, but existing data does not yet allow
to conﬁrm this idea. Unraveling the role of SUMOylation for post-
stroke recovery requires long-term in vivo experiments, ideally
featuring SUMO-KD after ischemic lesion induction to discriminate
between SUMOylation inﬂuence on acute lesion development and
long-term functional recuperation.
9. Conclusions and future research directions
Numerous studies support the idea that SUMOylation plays an
important role in the cellular response to hypoxic-ischemic injury.
Since most of the effects can contribute to neuronal survival, the
assumption that SUMOylation can act as an endogenous neuro-
protective mechanism is an intriguing concept. However, future
researchwill have to ﬁll two signiﬁcant knowledge gaps. Firstly, the
increasing body of indirect evidence suggesting that SUMOylation
plays a role in the hypoxic-ischemic stress response in the brain
needs to be ultimately conﬁrmed by studies designed to provide
direct evidence. Secondly, a number of SUMOylation effects are
detrimental under conditions of hypoxic-ischemic stress, whereas
the central role of others is still not completely elucidated. This
situation is based on the fact that SUMOylation is not exclusively a
protective response mechanism. It rather fulﬁlls various decisive
regulatory roles and helpful functions for intracellular metabolic
processes in the steady state, both of which can nevertheless
become detrimental in a pathophysiological environment. Hence, a
M. Peters et al. / Neurochemistry International 107 (2017) 66e77 75more detailed investigation of these processes is required for a
deeper understanding of the overall ambiguous role of SUMOyla-
tion in the hypoxic-ischemic brain. Such understanding will be
decisive in future attempts to exploit SUMOylation for mediating
neuroprotective effects. Protective and detrimental SUMOylation
effects likely take place in one cell and affect many pathways
simultaneously, what for instance makes the conception of a drug-
based intervention particularly challenging.
Importantly, this future research includes exploration of
SUMOylation effects in cell types others than neurons that are
affected or contribute to the peri- and postischemic environment.
Astrocytes represent an important research subject due to their
supportive function for the neuronal compartment. However,
revealing the effects of SUMOylation in post-ischemic oligoden-
drocytes, microglia, and invading immune cells will also be pivotal
in this context. It will ﬁnally be decisive to understand which
clinical situations require and which interventional tools allow the
targeted manipulation of the post-ischemic SUMOylation response
in order to optimize its neuroprotective impact not only acutely, but
also in the long run.
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